↓ Skip to main content

Childhood Takayasu arteritis: disease course and response to therapy

Overview of attention for article published in Arthritis Research & Therapy, November 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news
3 news outlets
twitter
1 X user
facebook
1 Facebook page

Citations

dimensions_citation
61 Dimensions

Readers on

mendeley
62 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Childhood Takayasu arteritis: disease course and response to therapy
Published in
Arthritis Research & Therapy, November 2017
DOI 10.1186/s13075-017-1452-4
Pubmed ID
Authors

Florence A. Aeschlimann, Simon W. M. Eng, Shehla Sheikh, Ronald M. Laxer, Diane Hebert, Damien Noone, Marinka Twilt, Christian Pagnoux, Susanne M. Benseler, Rae S. M. Yeung

Abstract

Takayasu arteritis (TAK) is a large vessel vasculitis that rarely affects children. Data on childhood TAK are scarce. The aim of this study was to analyze the presenting features, course and outcome of children with TAK, compare efficacy of treatment regimens and identify high-risk factors for adverse outcome. A single-center cohort study of consecutive children fulfilling the EULAR/PRINTO/PReS criteria for childhood TAK between 1986 and 2015 was performed. Clinical phenotypes, laboratory markers, imaging features, disease course and treatment were documented. Disease activity was assessed using the Pediatric Vasculitis Disease Activity Score at each visit. disease flare defined as new symptoms and/or increased inflammatory markers necessitating therapy escalation and/or new angiographic lesions, or death. logistic regression tested relevant variables for flare. Kaplan-Meier analyses compared treatment regimens. Twenty-seven children were included; 74% were female, median age at diagnosis was 12.4 years. Twenty-two (81%) children presented with active disease at diagnosis. Treatment regimens included corticosteroids alone (15%), corticosteroids plus methotrexate (37%), cyclophosphamide (19%), or a biologic agent (11%). Adverse outcomes were documented in 14/27 (52%) children: two (7%) died within 6 months of diagnosis, and 13 (48%) experienced disease flares. The 2-year flare-free survival was 80% with biologic treatments compared to 43% in non-biologic therapies (p = 0.03); at last follow-up, biologic therapies resulted in significantly higher rates of inactive disease (p = 0.02). No additional outcome predictor was identified. Childhood TAK carries a high disease burden; half of the children experienced flares and 7% died. Biologic therapies were associated with better control of disease activity.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 62 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 11 18%
Researcher 7 11%
Student > Postgraduate 6 10%
Student > Doctoral Student 5 8%
Student > Bachelor 5 8%
Other 13 21%
Unknown 15 24%
Readers by discipline Count As %
Medicine and Dentistry 29 47%
Nursing and Health Professions 6 10%
Immunology and Microbiology 3 5%
Agricultural and Biological Sciences 2 3%
Pharmacology, Toxicology and Pharmaceutical Science 1 2%
Other 2 3%
Unknown 19 31%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 24. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 March 2018.
All research outputs
#1,569,336
of 25,382,440 outputs
Outputs from Arthritis Research & Therapy
#207
of 3,380 outputs
Outputs of similar age
#34,690
of 445,683 outputs
Outputs of similar age from Arthritis Research & Therapy
#5
of 53 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,380 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.2. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 445,683 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 53 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.